Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dyne Therapeutics Inc (NQ: DYN ) 32.59 -2.04 (-5.88%) Streaming Delayed Price Updated: 2:40 PM EDT, Sep 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 555,865 Open 34.62 Bid (Size) 32.54 (2) Ask (Size) 32.65 (2) Prev. Close 34.63 Today's Range 32.31 - 35.23 52wk Range 6.400 - 47.45 Shares Outstanding 58,310,703 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference September 23, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm September 20, 2024 From Bragar Eagel & Squire Via GlobeNewswire Performance YTD +149.58% +149.58% 1 Month -27.37% -27.37% 3 Month -8.52% -8.52% 6 Month +25.08% +25.08% 1 Year +275.95% +275.95% More News Read More DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm! September 16, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire DYNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Dyne Therapeutics, Inc. on Behalf of Dyne Stockholders and Encourages Investors to Contact the Firm September 10, 2024 From Bragar Eagel & Squire Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN) September 09, 2024 From Kirby McInerney LLP Via Business Wire DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm! September 08, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm September 04, 2024 From The Schall Law Firm Via Business Wire Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher September 03, 2024 Via Benzinga Exposures Fossil Fuels Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy September 03, 2024 Via Benzinga Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building September 03, 2024 Via Investor's Business Daily Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 03, 2024 Via Benzinga Nasdaq Dips Over 2%; US Construction Spending Falls In July September 03, 2024 Via Benzinga Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates September 03, 2024 Via Benzinga Topics Stocks Exposures US Equities Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session September 03, 2024 Via Benzinga Dyne Therapeutics Announces Key Leadership Appointments September 03, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts September 03, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference August 29, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity? August 21, 2024 Via Talk Markets Topics Stocks Exposures US Equities Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday? August 13, 2024 Via Benzinga Topics Economy Exposures Interest Rates DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 August 12, 2024 Via InvestorPlace Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 12, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details July 14, 2024 Via Benzinga Chart Of The Day: Dyne Therapeutics - Deeply Discounted July 10, 2024 Via Talk Markets Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease June 24, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress June 13, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
